What this study is
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
What's being tested
- Behavioral Self-Regulation Adherence Counseling
Intervention · BEHAVIORAL
Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
Study details
- Official title
- DOSE DETERMINATION TRIAL: The Start/Persist Studies
- Sponsor
- University of Connecticut
- Conditions
- HIV Infections
- Enrolling
- 400 people
- Starts
- 2020-09-01
- Est. completion
- 2026-11-30
- Design
- Single-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Confirmed HIV positive
- Confirmed prescribed antiretroviral therapy
- Confirmed non-adherent to anti-retroviral therapy
You can't join if
- Does not have access to a phone
- Does not have access to the internet
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openContact for every open site
- Seth Kalichman, PhD · Contact860-208-3706seth.k@uconn.edu
University of Connecticut
Storrs, Connecticut, United States
- Seth Kalichman, PhD · Principal investigator
RecruitingUniversity of Connecticut Field Site
Atlanta, Georgia, United States
Recruiting
Study team
Sponsor
University of Connecticut
Study ID H19-161
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.